| 摘要 |
<p>A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.</p> |
| 申请人 |
AVEO PHARMACEUTICALS INC. |
发明人 |
VINCENT, SYLVIE;MEETZE, KRISTAN;FENG, BIN;TYLER, STEVEN;BOTTEGA, STEVE;NICOLETTI, RICHARD;MCINTOSH, DONNA;GYURIS, JENO |
